TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33494479

Group type: COMPARATOR
Intervention: Abdominopelvic exercise program (AEP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Abdominopelvic exercise with postural instructions (AEPPI)
Number of subjects: 40
Study: 35317128

Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (3D‐CNN) algorithm for MRI images
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional CNN algorithm for MRI images
Number of subjects: 96
Study: 32028288

Group type: EXPERIMENTAL
Intervention: Pharmacological reversal of neuromuscular blockade
Number of subjects: 923

Group type: COMPARATOR
Intervention: Spontaneous recovery of neuromuscular blockade
Number of subjects: 923
Study: 34419597

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2008
Study: 32059695

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Children (KIDNET)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study: 32675599

Group type: EXPERIMENTAL
Intervention: TiPEEK cage
Number of subjects: 149

Group type: COMPARATOR
Intervention: PEEK cage
Number of subjects: 149
Study: 34636474

Group type: EXPERIMENTAL
Intervention: Transoral injection with hyaluronic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional percutaneous approach with hyaluronic acid
Number of subjects: 20
Study: 33682145

Group type: EXPERIMENTAL
Intervention: Acetate infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study: 34609048

Group type: EXPERIMENTAL
Intervention: 3.5 mm annular zone (0.5 second on, 1 second off; 45 mW/cm2)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 4.0 mm annular zone (1 second on, 1 second off; 30 mW/cm2)
Number of subjects: 27
Study: 32644127

Group type: EXPERIMENTAL
Intervention: KAF156 800 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: KAF156 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: KAF156 300 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: KAF156 100 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: KAF156 20 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 32989714

Group type: EXPERIMENTAL
Intervention: Generic skepticism (GSI)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Generic OCPs
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Generic drugs
Number of subjects: 862
Study: 35900313

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) at doses of 25, 100, 200, 400, and 800 µg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at doses of 50, 200, 500, 1000, and 2000 µg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) at doses of 100, 400, 800, 1600, and 3200 µg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) at therapeutic doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at therapeutic doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) at therapeutic doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) at highest/supratherapeutic doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) at highest/supratherapeutic doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) at comparable therapeutic doses (100 µg/day)
Number of subjects: 54
Study: 32816877

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study: 36054180

Group type: EXPERIMENTAL
Intervention: High intrinsic renal sodium avidity (IRSA)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Incremental loop diuretic dose titration after >24 h
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Low intrinsic renal sodium avidity (IRSA)
Number of subjects: 339
Study: 33658762

Group type: EXPERIMENTAL
Intervention: Retinol palmitate ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35743694

Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution (Optilyte®) 20 mL/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gelatine 26.500 Da (Geloplasma®) 20 mL/kg
Number of subjects: 25
Study: 32628751

Group type: EXPERIMENTAL
Intervention: Age of smoking initiation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cigarettes per day, smoking initiation, smoking cessation, coffee consumption
Number of subjects: 12
Study: 35229697

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training in addition to early passive motion protocol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Early passive motion protocol
Number of subjects: 22
Study: 33125516

Group type: EXPERIMENTAL
Intervention: Vericiguat 0.5–15.0 mg solution (first‐in‐human study) or 1.25–10.0 mg immediate release (IR tablets) single dose
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Vericiguat 1.25–10.0 mg IR tablets once daily (QD) or 5.0 mg IR tablets twice daily for 7 consecutive days
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Vericiguat 5.0 mg IR tablets with food
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Vericiguat 15.0 mg (oral solution, fasted)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Vericiguat ≤ 10.0 mg, IR tablets
Number of subjects: 265
Study: 35950339

Group type: EXPERIMENTAL
Intervention: Healthy Living Triple P–Positive Parenting Program (n = 22)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Care-as-usual (n = 28)
Number of subjects: 50
Study: 33788855

Group type: EXPERIMENTAL
Intervention: Baseline data including DXA obtained Subtotal fat percentage and Subtotal lean mass
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms
Number of subjects: 0
Study: 32176711

Group type: EXPERIMENTAL
Intervention: Oral Antithrombotic Treatment (OAT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenprocoumon or Warfarin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: INR Measurement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Recruitment Stages
Number of subjects: 100

Group type: COMPARATOR
Intervention: Age Comparison
Number of subjects: 100
Study: 36060518

Group type: EXPERIMENTAL
Intervention: Medical therapy (MED)
Number of subjects: 523

Group type: COMPARATOR
Intervention: CABG plus Medical therapy (CABG + MED)
Number of subjects: 523
Study: 34157357

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydralazine and Isosorbide Dinitrate (ISDNHYD)
Number of subjects: 0
Study: 32333162

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA)
Number of subjects: 739

Group type: COMPARATOR
Intervention: No Obstructive Sleep Apnea (Control)
Number of subjects: 739
Study: 34793868

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg once daily
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg once daily
Number of subjects: 931

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study: 34930152

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: mRNA Covid-19 vaccination (Moderna and Pfizer-BioNTech)
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 1233
Study: 36078394

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy + usual care
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study: 33612123

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM) combined with neuromuscular exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classical massage combined with the same set of exercises
Number of subjects: 20
Study: 32176364

Group type: EXPERIMENTAL
Intervention: High-pressure postdilatation using noncompliant balloons
Number of subjects: 810

Group type: COMPARATOR
Intervention: Moderate-pressure dilatation using stent balloons
Number of subjects: 810
Study: 35941553

Group type: EXPERIMENTAL
Intervention: Learning and Coping (LC)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Empowerment, Motivation and Medical Adherence (EMMA)
Number of subjects: 514
Study: 32324902

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32393220

Group type: EXPERIMENTAL
Intervention: Digital chest drainage system
Number of subjects: 102

Group type: COMPARATOR
Intervention: Analogue chest drainage system
Number of subjects: 102
Study: 35173020

Group type: EXPERIMENTAL
Intervention: Distal AC block
Number of subjects: 95

Group type: COMPARATOR
Intervention: Femoral triangle block
Number of subjects: 95

Group type: COMPARATOR
Intervention: Proximal AC block
Number of subjects: 95
Study: 34660225

Group type: EXPERIMENTAL
Intervention: Maternal mentoring program (health education, monitoring, text-message reminders)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no mentoring program)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Maternal mentoring program
Number of subjects: 205
Study: 32516351

Group type: COMPARATOR
Intervention: Secondary or post-secondary education
Number of subjects: 3984

Group type: COMPARATOR
Intervention: Highest asset quartile (most affluent)
Number of subjects: 3984

Group type: EXPERIMENTAL
Intervention: Lower SES
Number of subjects: 3984

Group type: EXPERIMENTAL
Intervention: Higher SES
Number of subjects: 3984
Study: 35485630

Group type: EXPERIMENTAL
Intervention: Teach back method (4 sessions, each 45 minutes)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Teach back method
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 33043691

Group type: EXPERIMENTAL
Intervention: Bupivacaine/Clonidine mixture
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 124
Study: 35850367

Group type: EXPERIMENTAL
Intervention: Black tea treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tannic acid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated pellicles
Number of subjects: 0
Study: 32221489

Group type: EXPERIMENTAL
Intervention: Mental/Incisive Nerve Block (MINB) using 4% Articaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block (IANB) using 4% Articaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MINB and IANB
Number of subjects: 0
Study: 36030106

Group type: EXPERIMENTAL
Intervention: 1PC111 (fixed-dose combination of pitavastatin 2 mg and ezetimibe 10 mg)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Pitavastatin (2 mg)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: 1PC111
Number of subjects: 388
Study: 34425869

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus fulvestrant
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 114
Study: 35760659

Group type: EXPERIMENTAL
Intervention: Customized guides (cutting guides and patient-fitted osteosynthesis plates)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CAD/CAM surgical splints
Number of subjects: 30
Study: 35213214

Group type: EXPERIMENTAL
Intervention: Adjuvant Sorafenib
Number of subjects: 2427
Study: 34620618

Group type: EXPERIMENTAL
Intervention: Glucagon autoinjector (GAI) 1 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Glucagon emergency kit (GEK) 1 mg
Number of subjects: 161
Study: 35282747

Group type: EXPERIMENTAL
Intervention: Educational intervention based on social cognitive theory
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 35167949

Group type: EXPERIMENTAL
Intervention: Auriculotherapy (AG)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Placebo (PG)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 91
Study: 34344286

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy rotation (PTR)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 35459911

Group type: EXPERIMENTAL
Intervention: Conventional milk (CON)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: a2 Milk™ (A2M)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lactose-free conventional milk (LF-CON)
Number of subjects: 40
Study: 36191669

Group type: EXPERIMENTAL
Intervention: 400 g portion size
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 500 g portion size
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 600 g portion size
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 700 g portion size
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Faster eating rate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Larger bite size
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Higher bite count
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Longer meal duration
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sensory-specific satiety (SSS)
Number of subjects: 44
Study: 34197792

Group type: EXPERIMENTAL
Intervention: Self-administered interRAI Check-Up Assessment (CUSR)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Lay interviewer-assisted interRAI Check-Up Assessment (CUSR)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Self-reported health needs assessment using CUSR
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Self-reported difficulty in completing the assessment
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Self-reported health status and phone use
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Participant feedback on CUSR items
Number of subjects: 184
Study: 32180369

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 532
Study: 35569035

Group type: EXPERIMENTAL
Intervention: Higher-dose combination group (180 μg albuterol and 160 μg budesonide)
Number of subjects: 3132

Group type: EXPERIMENTAL
Intervention: Lower-dose combination group (180 μg albuterol and 80 μg budesonide)
Number of subjects: 3132

Group type: COMPARATOR
Intervention: Albuterol-alone group (180 μg albuterol)
Number of subjects: 3132
Study: 34448709

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) provided to PrEP users (471 participants)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) provided to PrEP users
Number of subjects: 939

Group type: COMPARATOR
Intervention: Daily PrEP
Number of subjects: 939
Study: 32543684

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT (90 mg twice daily)
Number of subjects: 3056

Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month DAPT
Number of subjects: 3056
Study: 36296939

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with carrot-derived rhamnogalacturonan-I (cRG-I)
Number of subjects: 0
Study: 32682946

Group type: EXPERIMENTAL
Intervention: Posaconazole IV 3.5, 4.5 or 6.0 mg/kg/d for ≥10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole PFS at the identical dose for ≤18 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posaconazole IV and PFS
Number of subjects: 0
Study: 33017784

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide/50% oxygen
Number of subjects: 48

Group type: COMPARATOR
Intervention: 100% oxygen placebo
Number of subjects: 48
Study: 35764793

Group type: EXPERIMENTAL
Intervention: slow yogic breathing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: deep abdominal breathing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: deep diaphragmatic breathing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: deep chest breathing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: three-part breath (deep abdominal, deep diaphragmatic, deep chest breathing)
Number of subjects: 18

Group type: COMPARATOR
Intervention: spontaneous breathing
Number of subjects: 18
Study: 32735752

Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin or oxaliplatin, and capecitabine (ECC/EOC)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: VTE occurrence
Number of subjects: 781
Study: 34999830

Group type: EXPERIMENTAL
Intervention: Elective freeze
Number of subjects: 619
Study: 33077240

Group type: EXPERIMENTAL
Intervention: Reduced needle (20/17 gauge)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard needle (16 gauge)
Number of subjects: 95
Study: 34991428

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation combined with myofascial release technique
Number of subjects: 30
Study: 33755118

Group type: EXPERIMENTAL
Intervention: Learning and Coping Cardiac Rehabilitation (LC-CR)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (Control)
Number of subjects: 825
Study: 33266499

Group type: EXPERIMENTAL
Intervention: Energy-reduced anti-inflammatory diet
Number of subjects: 81
Study: 36239644

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 340

Group type: COMPARATOR
Intervention: Best medical care (control)
Number of subjects: 340
Study: 33531690

Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32700953

Group type: EXPERIMENTAL
Intervention: ProSAAF
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control
Number of subjects: 346
Study: 36002795

Group type: EXPERIMENTAL
Intervention: Visual scanning exercises along with task specific approach
Number of subjects: 64

Group type: COMPARATOR
Intervention: Task specific approach alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comparison of total scores between experimental and control groups
Number of subjects: 64
Study: 34686604

Group type: EXPERIMENTAL
Intervention: Language-matching intervention
Number of subjects: 0
Study: 32722799

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 570

Group type: COMPARATOR
Intervention: SRF presence at baseline
Number of subjects: 570

Group type: COMPARATOR
Intervention: Baseline fluid volumes
Number of subjects: 570
Study: 34918951

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks in nonproliferative diabetic retinopathy subgroup
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Liraglutide treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks in proliferative diabetic retinopathy subgroup
Number of subjects: 37
Study: 32705801

Group type: EXPERIMENTAL
Intervention: Intravenous propofol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 29
Study: 33988338

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus and prednisone (rabbit antithymocyte globulin/EVR)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus and prednisone (basiliximab/EVR)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Mycophenolate with tacrolimus and prednisone (basiliximab/mycophenolate)
Number of subjects: 288
Study: 34105796

Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of birth weight
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Multivariable MR analyses
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Three BMD phenotypes (eBMD, TB-BMD, FN-BMD)
Number of subjects: 500000
Study: 32516725

Group type: EXPERIMENTAL
Intervention: True indoor air filtration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham indoor air filtration
Number of subjects: 29
Study: 34371826

Group type: EXPERIMENTAL
Intervention: Exercise program alone (n = 11)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined-exercise program and nutrition supplement (n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control group (n = 12)
Number of subjects: 46
Study: 32143065

Group type: EXPERIMENTAL
Intervention: Enhanced recall intervention group (Memflex protocol)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Basic recall control group
Number of subjects: 31
Study: 35405087

Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus bevacizumab
Number of subjects: 160

Group type: COMPARATOR
Intervention: Weekly paclitaxel plus bevacizumab
Number of subjects: 160
Study: 32894227

Group type: EXPERIMENTAL
Intervention: Critical culprit lesion locations (CCLL)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Non-CCLL
Number of subjects: 626
Study: 33504408

Group type: EXPERIMENTAL
Intervention: Treprostinil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Incremental exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Constant work rate exercise
Number of subjects: 14
Study: 36344933

Group type: EXPERIMENTAL
Intervention: Nomogram for prediction of severe CAP development based on chronic kidney dysfunction, malignant tumor, abnormal neutrophil count, abnormal lymphocyte count, decreased serum albumin level, and increased HbA1c level at admission.
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Nomogram for prediction of severe CAP development
Number of subjects: 1026
Study: 33164978

Group type: EXPERIMENTAL
Intervention: Adapted exercises plus general exercise recommendations
Number of subjects: 18

Group type: COMPARATOR
Intervention: General exercise recommendations
Number of subjects: 18
Study: 34347237

Group type: EXPERIMENTAL
Intervention: Continuous erector spinae plane block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 80